Posted inBiotechnology
Aspen enriches Parkinson’s cell therapy trial with Kite-backed $115M series C
Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ongoing…
Posted inBiotechnology
GSK picks Flagship’s Quotient, ProFound as 1st biotech partners for $7B pact
GSK has picked a novel protein biotech and a genomics biotech as its first collaborators under a $7 billion biobucks…
Posted inBiotechnology
Merck KGaA links up with Flagship’s Valo Health in search for Parkinson’s targets, offers $3B in biobucks
Merck KGaA has become the latest Big Pharma to tap the drug discovery expertise of Flagship Pioneering’s Valo Health. The…
Posted inBiotechnology
ExamOne executive details how mobile phlebotomy is reshaping clinical research
Mobile phlebotomy is playing a growing role in clinical research as trial sponsors turn to at-home services to improve access…
Posted inBiotechnology
Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO
After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience and bringing…
Posted inBiotechnology
Quest Diagnostics highlights role of in vitro diagnostics in precision medicine
Quest Diagnostics is emphasizing the critical role of in vitro diagnostics (IVDs) in shaping modern healthcare and advancing precision medicine,…
Posted inMedical Technology
FDA clears Dexcom’s Type 2 diabetes software for optimizing basal insulin doses
Dexcom has obtained an FDA clearance for its basal insulin dosing optimizing program, designed for adults with Type 2 diabetes…
Posted inBiotechnology
Celltrion still thinking bigger than biosimilars with option for $350M antibody deal
Korea’s Celltrion is continuing to think bigger than biosmilars, this time securing the option to use TriOar’s antibody platform in…
Posted inMedical Technology
Radiology provider Lumexa Imaging eyes IPO expected to raise $200M
Lumexa Imaging, formerly known as US Radiology Specialists, has filed with the SEC to go public and is set to…
Posted inBiotechnology
Merck’s HIV combo matches Gilead’s Biktarvy in latest phase 3 test for islatravir
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule…